DE277022C - - Google Patents
Info
- Publication number
- DE277022C DE277022C DENDAT277022D DE277022DA DE277022C DE 277022 C DE277022 C DE 277022C DE NDAT277022 D DENDAT277022 D DE NDAT277022D DE 277022D A DE277022D A DE 277022DA DE 277022 C DE277022 C DE 277022C
- Authority
- DE
- Germany
- Prior art keywords
- effect
- phenetidine
- antipyretic
- new
- antineuralgic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IMPPGHMHELILKG-UHFFFAOYSA-N 4-ethoxyaniline Chemical compound CCOC1=CC=C(N)C=C1 IMPPGHMHELILKG-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 14
- 239000002221 antipyretic Substances 0.000 description 5
- -1 bromoisovalerylaminoacetate-p-phenetidine Chemical compound 0.000 description 5
- 230000001754 anti-pyretic Effects 0.000 description 4
- HOLXDUWCWUTUGD-UHFFFAOYSA-N 4-(4-aminophenoxy)butan-2-one Chemical compound CC(=O)CCOC1=CC=C(N)C=C1 HOLXDUWCWUTUGD-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- WMFATTFQNRPXBQ-UHFFFAOYSA-N 2-bromopentanoic acid Chemical compound CCCC(Br)C(O)=O WMFATTFQNRPXBQ-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000000147 hypnotic Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- RQLZQHFUAKKMNC-UHFFFAOYSA-N 2-bromo-3-methylbutanamide Chemical compound CC(C)C(Br)C(N)=O RQLZQHFUAKKMNC-UHFFFAOYSA-N 0.000 description 1
- UEBARDWJXBGYEJ-UHFFFAOYSA-N 2-bromo-3-methylbutanoic acid Chemical class CC(C)C(Br)C(O)=O UEBARDWJXBGYEJ-UHFFFAOYSA-N 0.000 description 1
- HFAUMPWMNPYULN-UHFFFAOYSA-N 2-bromo-3-methylbutanoyl bromide Chemical compound CC(C)C(Br)C(Br)=O HFAUMPWMNPYULN-UHFFFAOYSA-N 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- UBJQQNDVOGPBGU-UHFFFAOYSA-N [Br-].CCOC1=CC=C([NH3+])C=C1 Chemical compound [Br-].CCOC1=CC=C([NH3+])C=C1 UBJQQNDVOGPBGU-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960000539 carbamide Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
KAISERLICHESIMPERIAL
PATENTAMT.PATENT OFFICE.
PATENTSCHRIFTPATENT LETTERING
- JVi 277022 KLASSE 12 o. GRUPPE- JVi 277022 CLASS 12 or GROUP
Dr. PETER BERGELL in BERLIN-WILMERSDORF.Dr. PETER BERGELL in BERLIN-WILMERSDORF.
Verfahren zur Herstellung eines Acylderivats von p-Phenetidin.Process for the preparation of an acyl derivative of p-phenetidine.
Patentiert im Deutschen Reiche vom 17. September 1912 ab.Patented in the German Empire on September 17, 1912.
Einer Reihe von Fiebermitteln kommt eine sedative und antineuralgische Wirkung zu. Auch wird einigen Fiebermitteln nachgerühmt, daß sie den Eintritt des natürlichen Schlafens befördern. Wir besitzen jedoch kein synthetisches Arzneimittel, das aufgebaut ist aus zwei Gruppen, von denen die eine einem bekannten Schlafmittel, die andere einem bekannten Antipyreticum zugrunde liegt. Es liegen hierA number of antipyretic agents have sedative and antineuralgic effects. Some antipyretic drugs are also praised for the fact that they induce natural sleep promote. However, we do not have a synthetic drug made up of two Groups, one of which is known to a sleep aid, the other to a known Is based on antipyreticum. It's here
ίο zwei Probleme vor. Einmal kann in einem Stoff ein Sedati vum und ein Fiebermittel gebunden sein, die z. B. bei der hydrolytischen Spaltung unversehrt resultieren. Ein derartiger Fall liegt z. B. bei dem bekannten Bromisovalerylaminoacetat-p-phenetidin vor. Es kann aber auch ein Körper synthetisiert werden, der durch Spaltung niemals die beiden pharmakologischen Komponenten ergibt, in seinem Bau aber sowohl einem Schlafmittel wie einem Antipyreticum ähnlich ist. Nur bei diesem letzteren Typus sind zudem molekulare Wirkungen möglich, die anderer Art sind als die Wirkungen der Komponenten.ίο two problems. Once can in one Substance a Sedati vum and an antipyretic be bound, the z. B. the hydrolytic Cleavage result intact. Such a case is e.g. B. in the known bromoisovalerylaminoacetate-p-phenetidine before. But a body can also be synthesized which, by splitting, never divides the two pharmacological ones Components, but its structure is similar to both a sleeping pill and an antipyretic. Only with this one of the latter type, molecular effects of a different kind are also possible Effects of the components.
So wurde eine Kombinationswirkung da-So a combination effect was created
7.5 durch gefunden, daß man den a-Bromisovaleriansäurerest mit p-Phenetidin analog den Synthesen des Acetyl-p-phenetidins vereinigt. Es wurde durch Reaktion von zwei Molekülen p-Phenetidin mit Bromisovalerylbromid in benzolischer Lösung Bromisovalerylphenetidin erhalten, das sich leicht durch Umkristallisieren aus verdünntem Alkohol von dem entstehenden bromwasserstoffsauren Phenetidin befreien läßt. Es zeigt sich, daß die Brom-Substitution die Reaktion nicht hindert. Der neue Körper schmilzt scharf bei 151°, ist in 45 7.5 found that the a-bromoisovaleric acid residue is combined with p-phenetidine analogously to the synthesis of acetyl-p-phenetidine. The reaction of two molecules of p-phenetidine with bromoisovaleryl bromide in a benzene solution gave bromoisovalerylphenetidine, which can easily be freed from the resulting hydrobromic acid phenetidine by recrystallization from dilute alcohol. It turns out that the bromine substitution does not hinder the reaction. The new body melts sharply at 151 °, is in 45
Wasser schwer löslich. Aus verdünntem Alkohol scheidet er sich in großen säulenförmigen Kristallen ab, die wasserfrei sind. Die physiologische Wirkung der neuen Verbindung entspricht in einer bestimmten Richtung der Kombination des Bromvaleriansäure- und Phenetidincharakters. Sie wirkt schlafmachend im Sinne des Bromisovaleriansäureamids oder Carbamids, setzt die Körpertemperatur des gesunden wie fiebernden Menschen nicht oder nur ganz unwesentlich herab, wirkt also nicht antipyretisch, jedoch außerordentlich antineuralgisch und ist sehr wenig giftig. 1 g tötet ein mittleres Kaninchen von 3 kg nicht. Die hypnotische antineuralgische Wirkung setzt schnell ein. Jegliche posthypnotische Nebenwirkung fehlt. Bei dem neuen Stoff greift vor allem die antineuralgische Wirkung der Seitenkette potenzierend ineinander, indem durch die erstere sowohl den Eintritt des Schlafes hemmende Sensationen, Kopfschmerz und ähnliche Erscheinungen ausgeschaltet wie posthypnotische Nebenwirkungen verhindert werden. Die neue Synthese ergibt nach den Versuchen erstens eine Verbesserung des Bromisovaleriansäurecarbanids und zweitens einen speziellen Effekt, der nicht als Summenwirkung, sondern als Ausdruck des ganzen Moleküls eines Antineuralgicums und Hypnoticums aufzufassen ist. Das neue Produkt unterscheidet sich gegenüber den einfachen Gemischen der analogen bekannten Bromisovaleriansäurederivate mit Acetyl-p-phenetidin vorteilhaft durch die stärkere antineuralgische und analgetische Wirkung. Auch ist für eine Anzahl von Fällen der Wegfall der antipy-Hardly soluble in water. From diluted alcohol it separates into large columnar forms Crystals that are anhydrous. The physiological effect of the new compound corresponds in a certain direction to the combination of bromovaleric acid and phenetidine character. It has a sleep-inducing effect in the sense of bromoisovaleric acid amide or carbamide, sets the body temperature of the healthy and feverish people do not or only marginally downgrade, so it does not work antipyretic, but extremely anti-neuralgic and very little poisonous. 1 g kills a medium rabbit of 3 kg does not. The hypnotic antineuralgic effect continues quickly one. There is no post-hypnotic side effect. The new material works especially the anti-neuralgic effect of the side chain by potentiating one another through the former, sensations inhibiting the onset of sleep, headache and similar phenomena are eliminated as posthypnotic side effects are prevented will. According to the experiments, the new synthesis firstly results in an improvement in the bromoisovaleric acid carbanide and secondly, a special effect, which is not a cumulative effect, but an expression of the whole molecule is to be understood as an antineuralgic and hypnotic. The new product makes a difference compared to the simple mixtures of the analogous known bromoisovaleric acid derivatives with acetyl-p-phenetidine beneficial due to the stronger antineuralgic and analgesic effect. In a number of cases, the elimination of the antipy-
5555
6060
7070
retischen Wirkung erwünscht, wie z. B. bei besonders blutarmen Personen.retic effect desired, such as. B. in particularly anemic people.
Nach der Konstitutionsformel ist auch anzunehmen, daß die Wirkung eine Wirkung sui generis ist und nicht erst eine Komponentenwirkung nach Verseifung des Produktes im Organismus. Aus den Untersuchungen über die verschiedene Wirkung des Bromisovalerianylamids und Bromisovalerianylcarbanids ist bekannt, daß es nicht der Bromvaleriansäurerest allein ist, der wirkt, sondern daß es auf den Charakter des ganzen Moleküls ankommt. Die alte Lehre, daß die Wirkung des Acetyl-p-phenetidins eine reine Wirkung des abgespaltenen p-Phenetidins wäre, ist nicht mehr aufrechterhalten worden. Auch der vorliegende Fall widerlegt sie völlig, da bei dem neuen Produkt einwandfrei nachgewiesen wurde, daß eine antipyretische Wirkung nicht ausgeübt wird.According to the constitutional formula, it can also be assumed that the effect is an effect is sui generis and not only a component effect after saponification of the product in the organism. From the studies on the various effects of bromoisovalerianylamide and bromoisovalerianylcarbanide is known not to be the bromovaleric acid residue the only thing that is effective is that it depends on the character of the whole molecule. The old doctrine that the effect of acetyl-p-phenetidine would be a pure effect of the split-off p-phenetidine no longer been sustained. The present case also completely refutes them, there the new product has been proven to have an antipyretic effect is not exercised.
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
DE277022C true DE277022C (en) |
Family
ID=533165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DENDAT277022D Active DE277022C (en) |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE277022C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3264344A (en) * | 1962-09-13 | 1966-08-02 | Hoffmann La Roche | Arylamides of beta, beta-dimethyl-alpha, gamma-dihydroxy butyric acid and their alkanoyl ester derivatives |
-
0
- DE DENDAT277022D patent/DE277022C/de active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3264344A (en) * | 1962-09-13 | 1966-08-02 | Hoffmann La Roche | Arylamides of beta, beta-dimethyl-alpha, gamma-dihydroxy butyric acid and their alkanoyl ester derivatives |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68910834T2 (en) | Use of resiniferatoxin and its analogs to make the inflammation-sensitive C-fiber insensitive by temperature control. | |
DE2015447B2 (en) | Muscle relaxant medicine | |
DE2241742A1 (en) | MEDICINAL PRODUCTS FOR THE EXTERNAL TREATMENT OF CONNECTIVE TISSUE DISEASES | |
DE1470014C3 (en) | 2-anilinonicotinic acid derivatives and processes for their preparation | |
DE277022C (en) | ||
DE2252637B2 (en) | Use of 1,3-glycerol dieters | |
AT67845B (en) | Process for the preparation of α-bromoisovaleric acid-p-phenetidine. | |
DE549631C (en) | Insect repellants | |
DE891323C (en) | Cosmetic product | |
DE198715C (en) | ||
DE2521905C2 (en) | Medicines to promote cerebral blood flow | |
DE317211C (en) | ||
DE506889C (en) | Process for the preparation of pyrethrum extract emulsions | |
DE2257285C3 (en) | Pharmaceutical preparation containing l ^ -DiphenyM-n-butyM-hydroxymethyl-S ^ -dioxopyrazolidine half succinate | |
DE1695832C3 (en) | B1,3-biphenylpyrazoline derivatives and process for their preparation | |
DE1617542A1 (en) | Process for the preparation of stable solutions of lecithin, especially soybean lecithin, in aqueous, sugary alcohol | |
Roll et al. | Studies on the teratogenic effects of hydroxyurea during the early and embryonic development in mice | |
DE557991C (en) | Process for the production of long-lasting, oily solutions, suitable for injection purposes, of insoluble or sparingly soluble glucosides in oils | |
DE470955C (en) | Process for the preparation of solutions of basic quinine in oils | |
DE485198C (en) | Process for obtaining uniform compounds from the alcohols in wool fat | |
DE389880C (en) | Process for the preparation of a liquid derivative of 1-phenyl-2,3-dimethyl-5-pyrazolone | |
DE590312C (en) | Process for the preparation of compounds of chloral and its homologues with quinine | |
DE453193C (en) | Means with fungicidal and insecticidal effects | |
AT164567B (en) | Process for the production of sterols or their addition products from mixtures or solutions containing sterols | |
DE752571C (en) | Process for the preparation of compounds of guaiacol |